Design Therapeutics (DSGN) FCF Margin (2020)

Design Therapeutics' (DSGN) quarterly FCF Margin came in at 8660.61% in Q4 2020, up 6.83% quarter-over-quarter from 9295.0% in Q3 2020.

Design Therapeutics (DSGN) FCF Margin (2020) Analysis & Trends

Design Therapeutics has disclosed FCF Margin across 1 years of filings, most recently posting 8660.61% for Q4 2020.

FCF Margin for Q4 2020 came in at 8660.61%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2020 was 3842.04% (changed N/A YoY), and the FY2020 annual result was 3869.47%, changed N/A from the prior year.
FCF Margin came in at 8660.61% for Q4 2020 at Design Therapeutics, up from 9295.0% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 1872.54% in Q1 2020 to a low of 9295.0% in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-3.98%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	43.35%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Design Therapeutics	763.94 Mn	541.11 Mn	-	-

Download Data